Q-omics provides the consensus-scored IFI30 profile across patient tissues and cancer cell-line models. IFI30 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IFI30 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, IFI30 protein abundance shows 23,187 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where IFI30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFI30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFI30 survival associations across molecular data types. IFI30 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFI30 RNA expression–survival associations across cancer types. High IFI30 expression shows unfavorable associations in KIRC, LGG and GBM, but favorable associations in SKCM, HNSC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IFI30 RNA expression.
This table summarizes IFI30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IFI30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFI30 shows higher tumor expression in KIRC, HNSC, COAD, KIRP, STAD and LIHC. The KIRC box plot shows higher IFI30 RNA expression in tumor versus normal tissue (log2 FC = +0.993, t-test p < 0.001).
This table shows molecular features associated with IFI30 in patient tissues and cancer cell lines. In patient samples, IFI30 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFI30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
